20 November 2020 - Today, the U.S. FDA approved Zokinvy (lonafarnib) capsules to reduce the risk of death due to Hutchinson-Gilford progeria syndrome and for the treatment of certain processing-deficient progeroid laminopathies in patients one year of age and older. 

Zokinvy is not approved for use in patients with other progeroid syndromes or laminopathies.

The FDA granted this application priority review designation. Zokinvy received orphan drug designation, which provides incentives to assist and encourage the development of drugs for rare diseases, and breakthrough therapy designation. In addition, the manufacturer received a rare paediatric disease priority review voucher.

Read FDA press release